Publication:
Nephrogenic systemic fibrosis

dc.contributor.authorRathachai Kaewlaien_US
dc.contributor.authorHani Abujudehen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherMassachusetts General Hospitalen_US
dc.date.accessioned2018-06-11T05:08:43Z
dc.date.available2018-06-11T05:08:43Z
dc.date.issued2012-07-01en_US
dc.description.abstractOBJECTIVE. The purpose of this article is to discuss nephrogenic systemic fibrosis (NSF) in detail regarding its history, possible pathophysiology, clinical and pathologic presentations, diagnosis, and implications for the radiology community. CONCLUSION. NSF is a potentially lethal disorder that occurs in patients with reduced kidney function. Current evidence suggests a strong association with gadolinium-based contrast agents - mostly used in MRI - in this patient group. This has urged the radiology community to emphasize careful screening for the presence of renal dysfunction among patients for whom gadolinium-enhanced MRI is contemplated. Appropriate selection of gadolinium-based contrast agent type, avoidance of nonstandard dosage, patient education, and informed consent have been recommended by authorities. © American Roentgen Ray Society.en_US
dc.identifier.citationAmerican Journal of Roentgenology. Vol.199, No.1 (2012)en_US
dc.identifier.doi10.2214/AJR.11.8144en_US
dc.identifier.issn15463141en_US
dc.identifier.issn0361803Xen_US
dc.identifier.other2-s2.0-84863638733en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/14750
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84863638733&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleNephrogenic systemic fibrosisen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84863638733&origin=inwarden_US

Files

Collections